Name: Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model (Video) | JoVE Journal
Uploaded: 2022-03-05T13:30:00.000+00:00
Duration: 9 min 44 s
Description: Learn to quantify hepatic glucose production in a PCOS mouse model using stable isotopic glucose tracers and GCMS analysis. This method enables accurate measurement of metabolic dysregulation in fasting and glucose-rich states.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by training grants by the Department of Obstetrics and Gynecology, Baylor College of Medicine (ALG) and R-01 research grant (Grant # DK114689) for CSB, SC and JM from National Institutes of Health.

All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Baylor College of Medicine.
1. Preparation of [6,6-2H2]glucose
<ol>
	<li>One day before the procedure, prepare the stable isotope glucose tracer in normal saline. For this experiment, [6,6-2H2]glucose was used as a tracer to measure plasma glucose appearance rate. 
	NOTE: In this experiment, glucose production during fasting and glucose-rich conditions were measured, so the glucose isotope was prepared in two different preparations. Prepare the solutions in such a way that the final infusing dose will be close to 1 mg/(kg&#183;min) and 2 mg/(kg&#183;min), respectively. These concentrations were optimized by several prior pilot studies.</li>
	<li>Prepare the first infusate with only [6,6-2H2]glucose as a tracer to represent the fasting condition by dissolving sterile and pyrogen free [6,6-2H2]glucose in sterile 0.9% sodium chloride solution.</li>
	<li>Prepare the second infusate by dissolving both [6,6-2H2]glucose tracer along with non-isotopic glucose (~20 mg/kg&#183;min) in sterile 0.9% sodium chloride solution to simulate the fed condition. 
	NOTE: In the present experiment, a primed constant rate infusion of [6,6-2H2]glucose at (~) 1.08 mg/(kg&#183;min) (fasting condition) and (~) 1.9 mg/kg&#183;min (glucose rich condition) was used. In order to mimic the &#39;glucose rich condition&#39;, D-glucose infusion rate was set at (~) 18.8 mg/(kg&#183;min).</li>
	<li>Once the solutions are prepared, sterile filter the solutions with a 0.22 &#181;m filter and store at 4 &#176;C. Warm the solutions to room temperature prior to the infusion. Load the solutions on prelabeled 1 mL syringes.</li>
	<li>Set up the pump to facilitate a primed constant rate infusion of the first infusate (for basal condition) containing only the tracer, and program the pump for a constant rate infusion of the isotope at 150 &#181;L/h for 3 h.</li>
	<li>At the end of the 3 h fasting set up, replace the first infusate syringe with the second infusate syringe containing the isotopic tracer and D-glucose (for the simulated fed state), and prime the infusion for the intial 15 min at 600 &#181;L/h. Set the pump to a constant rate infusion at 150 &#181;L/h for the additional 3 h.</li>
</ol>
2. Set-up of infusion experiments
<ol>
	<li>Remove the mice from their home cages and place them in their fasting cages 3 h prior to the start of the experiment. For this experiment, a 4-month-old female mice from the C57BL/6J strain was used. 
	NOTE: This procedure does not require any analgesia prior to or during the procedure given its minimally invasive nature.</li>
	<li>Assemble the caging equipment by grouping the mice into a set number of mice per insulin pump. Place partitions on top of a flat, stable base to make individual stalls for the mice. It is important to have access to the tail vein catheter for the infusion to run, so ensure that there is a notch in the bottom of the cage door. 
	NOTE: Cages shown in the video were made specifically for this experiment. Cages are clear and made out of plexiglass. There is a flat, stable base (standard caging equipment) upon which the partitions sit. This setup consists of several pieces to allow ease of setup in several different environments depending on the height of the table and the needs of the experimenter. The door to the cage slides to close and has a notch at the bottom to allow the tail to fit through.</li>
	<li>Assemble the 1&#160;mL syringes containing 1 mL of basal infusate, and then connect to the infusion pump tubing using the polyethylene tubing 0.28 mm ID x 0.61 mm.</li>
	<li>Prepare the infusion pump by setting the rate to 150 &#181;L/h, which is the basal rate.</li>
	<li>Heat a water bath to 48 &#176;C.</li>
	<li>Prepare the catheter insertion station adjacent to the water bath containing the 30 G 0.5 inch needles, 0.3 mm ID x 0.64 mm silastic tubing, and 1 inch clear transpore tape.</li>
	<li>After 3 h of fasting, begin the catheter insertion process, which is detailed below.</li>
</ol>
3. Catheter insertion
<ol>
	<li>Select one mouse and place it in a secure holder with access to the tail. An example of what to use is a bottle cut in half with a notch for the tail. Place the holder on a flat base. Place a piece tape over the proximal portion of the tail to allow space for catheter insertion more distally. 
	NOTE: The type of tape chosen for this task must have moderate strength and adhesiveness. Multipurpose, paper-based labeling tape was used in this experiment as it is mild and easy to peel off.</li>
	<li>Prepare the catheter (30 G needle attached to 0.3 mm silastic tubing and PE- 10 were gas sterilized) by attaching it to a 1 mL syringe containing sterile heparinized saline flush. Flush the catheter gently.</li>
	<li>Bring the mouse to the water bath and insert the tail in the water bath for approximately 30-45 s. This helps to dilate the tail vasculature for catheter placement.</li>
	<li>Perform the catheter insertion under sterile conditions. Once the tail is warmed, clean the tail with benzalkonium wipes and place a small copper, toothless alligator clamp, that was previously contoured to the shape of the tail, as a tourniquet at the proximal end of the tail. Visualize the lateral tail vein under a magnifying glass, and then carefully insert the catheter into the tail vein and withdraw the needle. Flush the solution gently to ensure patency of the catheter.</li>
	<li>Wrap a piece of 1 inch transpore tape around the insertion site to secure the catheter. Remove the small tourniquet from the tail.</li>
</ol>
4. Infusion set-up and first infusion
<ol>
	<li>Place the mouse in its individual cage and close the sliding door, ensuring the tail is protruding through the notch and remains outside of the cage.</li>
	<li>Place an additional piece of tape over the whole catheter and the tail to secure it to the base plate of the cage. Multipurpose colored, label tape was used for this step.</li>
	<li>Disconnect the flush from the tail vein catheter and place a small clamp on the catheter&#39;s silastic tubing to prevent backflow while connecting the infusate line from the pump.</li>
	<li>Once securely connected, remove the clamp and flush with the priming solution, which consists of the infusate. Ensure that the solution is clear in the tubing and not blood-stained.</li>
	<li>Make note of the time of initiation of the infusion to ensure that it runs for the total time of approximately 3 h. If multiple cages are used simultaneously, they should be staggered to manage infusion times effectively.</li>
	<li>Once infusion lines are noted to be functioning properly, remove the cover from the mouse. Place standard bedding around the mouse.</li>
	<li>Start the infusion with the first infusate containing the tracer and run it for 3 h continuously. For the duration of the infusion, continue to check mice wellbeing as well as infusion lines. Ensure that the infusion tubing is properly secured and that there are no leaks from the line connection points.</li>
</ol>
5. Blood sampling
<ol>
	<li>After the first infusion has completed, stop the infusion, place a clamp on the sylastic tubing on the catheter to prevent back flow. Gently remove the mice from their enclosures without disturbing the catheter in order to collect blood. Place them at a spot near the cages for blood draw. For this experiment, the mice underwent cheek venipuncture using a 4 mm lancet.</li>
	<li>Collect ~75 &#181;L of blood in the desired vial. To deproteinize samples in preparation for mass spectrometry, add approximately 15 &#181;L of blood to 500 &#181;L of acetone. The remaining blood can be used to check the blood glucose level via the glucometer and/or centrifuged to separate plasma for future hormone assays.</li>
</ol>
6. Second infusion
<ol>
	<li>Remove the infusates from the syringe pumps by disconnecting the tubing from the syringes and replace it with the second infusate containing the tracer along with the glucose. Repeat steps 4.2 through 4.7 using the glucose-rich isotopic glucose infusion.
	<ol>
		<li>To reach a steady state, run a bolus of the second infusate at 600 &#181;L/h for 15 min. Note the starting time for each group of cages. Decrease the infusion rate to 150 &#181;L/h to complete the 3 h of total infusion time.</li>
	</ol>
	</li>
	<li>Repeat steps 5.1 and 5.2.</li>
	<li>Stop the infusion pump and remove the tail vein catheter gently, apply pressure at the catheter sites until the bleeding stops, and return mice to their home cages.</li>
	<li>Santize and disinfect the caging setup thoroughly with standard soap and water. 
	NOTE: This is a survival procedure. Mice can be returned to cages and kept for further experiements if needed. It is recommended that no further experiementation is performed for at least a week following this procedure to ensure adequate animal welfare.</li>
</ol>
7. Mass spectrometry
<ol>
	<li>Send out the samples for mass spectrometry.</li>
	<li>Analyses
	<ol>
		<li>Measure the isotopic enrichment of [6,6-2H2]glucose by gaschromatography - mass spectrometry (GCMS) using the pentaacetate derivative21,22. Briefly, this method involves preparation of the pentaacetate derivative of glucose, followed by sample analysis using GCMS 20,22.</li>
	</ol>
	</li>
	<li>Calculations
	<ol>
		<li>Perform all kinetic measurements under steady state conditions. Total plasma glucose appearance rate (glucose Ra) was calculated from the M+2 enrichment of [6,6-2H2]glucose in plasma using established isotope dilution equations21. Under steady state conditions, it is assumed that the rate of appearance of glucose is equal to the rate of disappearance of glucose. Rate of endogenous glucose production (mg/(kg&#183;min)) (GPR) = glucoseRa - exogenous glucose.</li>
	</ol>
	</li>
</ol>

<ol><li>March, W. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+prevalence+of+polycystic+ovary+syndrome+in+a+community+sample+assessed+under+contrasting+diagnostic+criteria%5BTitle%5D)+AND+%22Human+Reproduction%22%5BJournal%5D)">The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.</a> Human Reproduction. 25 (2), 544-551 (2009).</li>
<li>Yildiz, B. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prevalence%2C+phenotype+and+cardiometabolic+risk+of+polycystic+ovary+syndrome+under+different+diagnostic+criteria%5BTitle%5D)+AND+%22Human+Reproduction%22%5BJournal%5D)">Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.</a> Human Reproduction. 27 (10), 3067-3073 (2012).</li>
<li>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Revised+2003+consensus+on+diagnostic+criteria+and+long-term+health+risks+related+to+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22Fertility+and+Sterility%22%5BJournal%5D)">Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.</a> Fertility and Sterility. 81 (1), 19-25 (2004).</li>
<li>Goodarzi, M. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Polycystic+ovary+syndrome%3A+etiology%2C+pathogenesis+and+diagnosis%5BTitle%5D)+AND+%22Nature+Reviews.+Endocrinology%22%5BJournal%5D)">Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.</a> Nature Reviews. Endocrinology. 7 (4), 219-231 (2011).</li>
<li>Azziz, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Introduction%3A+Determinants+of+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22Fertility+and+Sterility%22%5BJournal%5D)">Introduction: Determinants of polycystic ovary syndrome.</a> Fertility and Sterility. 106 (1), 4-5 (2016).</li>
<li>Baskind, N. E., Balen, A. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hypothalamic-pituitary%2C+ovarian+and+adrenal+contributions+to+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22Best+Practice+and+Research.+Clinical+Obstetrics+%26+Gynaecology%22%5BJournal%5D)">Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.</a> Best Practice and Research. Clinical Obstetrics & Gynaecology. 37, 80-97 (2016).</li>
<li>Burghen, G. A., Givens, J. R., Kitabchi, A. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Correlation+of+hyperandrogenism+with+hyperinsulinism+in+polycystic+ovarian+disease%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Endocrinology+and+Metabolism%22%5BJournal%5D)">Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.</a> The Journal of Clinical Endocrinology and Metabolism. 50 (1), 113-116 (1980).</li>
<li>Bremer, A. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Polycystic+ovary+syndrome+in+the+pediatric+population%5BTitle%5D)+AND+%22Metabolic+Syndrome+and+Related+Disorders%22%5BJournal%5D)">Polycystic ovary syndrome in the pediatric population.</a> Metabolic Syndrome and Related Disorders. 8 (5), 375-394 (2010).</li>
<li>Dunaif, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Excessive+insulin+receptor+serine+phosphorylation+in+cultured+fibroblasts+and+in+skeletal+muscle.+A+potential+mechanism+for+insulin+resistance+in+the+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Investigation%22%5BJournal%5D)">Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.</a> The Journal of Clinical Investigation. 96 (2), 801-810 (1995).</li>
<li>Højlund, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Impaired+insulin-stimulated+phosphorylation+of+Akt+and+AS160+in+skeletal+muscle+of+women+with+polycystic+ovary+syndrome+is+reversed+by+pioglitazone+treatment%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.</a> Diabetes. 57 (2), 357-366 (2008).</li>
<li>Moghetti, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Divergences+in+insulin+resistance+between+the+different+phenotypes+of+the+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Endocrinology+and+Metabolism%22%5BJournal%5D)">Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.</a> The Journal of Clinical Endocrinology and Metabolism. 98 (4), 628-637 (2013).</li>
<li>Ovalle, F., Azziz, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Insulin+resistance%2C+polycystic+ovary+syndrome%2C+and+type+2+diabetes+mellitus%5BTitle%5D)+AND+%22Fertility+and+Sterility%22%5BJournal%5D)">Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.</a> Fertility and Sterility. 77 (6), 1095-1105 (2002).</li>
<li>Dunaif, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Profound+peripheral+insulin+resistance%2C+independent+of+obesity%2C+in+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.</a> Diabetes. 38 (9), 1165-1174 (1989).</li>
<li>Hutchison, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effects+of+exercise+on+insulin+resistance+and+body+composition+in+overweight+and+obese+women+with+and+without+polycystic+ovary+syndrome%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Endocrinology+Metabolism%22%5BJournal%5D)">Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome.</a> The Journal of Clinical Endocrinology Metabolism. 96 (1), 48-56 (2011).</li>
<li>Stepto, N. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Women+with+polycystic+ovary+syndrome+have+intrinsic+insulin+resistance+on+euglycaemic-hyperinsulaemic+clamp%5BTitle%5D)+AND+%22Human+Reproduction%22%5BJournal%5D)">Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.</a> Human Reproduction. 28 (3), 777-784 (2013).</li>
<li>Basu, R., Schwenk, W. F., Rizza, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Both+fasting+glucose+production+and+disappearance+are+abnormal+in+people+with+%26%2334%3Bmild%26%2334%3B+and+%26%2334%3Bsevere%26%2334%3B+type+2+diabetes%5BTitle%5D)+AND+%22American+Journal+of+Physiology%2C+Endocrinology+and+Metabolism%22%5BJournal%5D)">Both fasting glucose production and disappearance are abnormal in people with &#34;mild&#34; and &#34;severe&#34; type 2 diabetes.</a> American Journal of Physiology, Endocrinology and Metabolism. 287 (1), 55-62 (2004).</li>
<li>Blesson, C. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sex+dependent+dysregulation+of+hepatic+glucose+production+in+lean+Type+2+diabetic+rats%5BTitle%5D)+AND+%22Frontiers+in+Endocrinology%22%5BJournal%5D)">Sex dependent dysregulation of hepatic glucose production in lean Type 2 diabetic rats.</a> Frontiers in Endocrinology. 10, Lausanne. 538(2019).</li>
<li>Caldwell, A. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Characterization+of+reproductive%2C+metabolic%2C+and+endocrine+features+of+polycystic+ovary+syndrome+in+female+hyperandrogenic+mouse+models%5BTitle%5D)+AND+%22Endocrinology%22%5BJournal%5D)">Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.</a> Endocrinology. 155 (8), 3146-3159 (2014).</li>
<li>Chappell, N. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prenatal+androgen+induced+lean+PCOS+impairs+mitochondria+and+mRNA+profiles+in+oocytes%5BTitle%5D)+AND+%22Endocrine+Connections%22%5BJournal%5D)">Prenatal androgen induced lean PCOS impairs mitochondria and mRNA profiles in oocytes.</a> Endocrine Connections. 9 (3), 261-270 (2020).</li>
<li>Chacko, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+gluconeogenesis+using+glucose+fragments+and+mass+spectrometry+after+ingestion+of+deuterium+oxide%5BTitle%5D)+AND+%22Journal+of+Applied+Physiology%22%5BJournal%5D)">Measurement of gluconeogenesis using glucose fragments and mass spectrometry after ingestion of deuterium oxide.</a> Journal of Applied Physiology. 104 (4), 944-951 (2008).</li>
<li>Bier, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+%26%2334%3Btrue%26%2334%3B+glucose+production+rates+in+infancy+and+childhood+with+6%2C6-dideuteroglucose%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">Measurement of &#34;true&#34; glucose production rates in infancy and childhood with 6,6-dideuteroglucose.</a> Diabetes. 26 (11), 1016-1023 (1977).</li>
<li>Chacko, S. K., Sunehag, A. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gluconeogenesis+continues+in+premature+infants+receiving+total+parenteral+nutrition%5BTitle%5D)+AND+%22Archives+of+Disease+in+Childhood.+Fetal+and+Neonatal+Edition%22%5BJournal%5D)">Gluconeogenesis continues in premature infants receiving total parenteral nutrition.</a> Archives of Disease in Childhood. Fetal and Neonatal Edition. 95 (6), 413-418 (2010).</li>
<li>Chacko, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effect+of+ghrelin+on+glucose+regulation+in+mice%5BTitle%5D)+AND+%22American+Journal+of+Physiology%2C+Endocrinology+and+Metabolism%22%5BJournal%5D)">Effect of ghrelin on glucose regulation in mice.</a> American Journal of Physiology, Endocrinology and Metabolism. 302 (9), 1055-1062 (2012).</li>
<li>Marini, J. C., Lee, B., Garlick, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Non-surgical+alternatives+to+invasive+procedures+in+mice%5BTitle%5D)+AND+%22Laboratory+Animals%22%5BJournal%5D)">Non-surgical alternatives to invasive procedures in mice.</a> Laboratory Animals. 40 (3), 275-281 (2006).</li>
<li>Jacobs, J. D., Hopper-Borge, E. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Carotid+artery+infusions+for+pharmacokinetic+and+pharmacodynamic+analysis+of+taxanes+in+mice%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%3A+JoVE%22%5BJournal%5D)">Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice.</a> Journal of Visualized Experiments: JoVE. (92), e51917(2014).</li>
<li>Ayala, J. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hyperinsulinemic-euglycemic+clamps+in+conscious%2C+unrestrained+mice%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%3A+JoVE%22%5BJournal%5D)">Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice.</a> Journal of Visualized Experiments: JoVE. (57), e3188(2011).</li>
<li>Kmiotek, E. K., Baimel, C., Gill, K. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Methods+for+Intravenous+Self+Administration+in+a+Mouse+Model%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%3A+JoVE%22%5BJournal%5D)">Methods for Intravenous Self Administration in a Mouse Model.</a> Journal of Visualized Experiments: JoVE. (70), e3739(2012).</li>
<li>Marini, J. C., Lee, B., Garlick, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+urea+kinetic+studies+in+conscious+mice%5BTitle%5D)+AND+%22The+Journal+of+Nutrition%22%5BJournal%5D)">In vivo urea kinetic studies in conscious mice.</a> The Journal of Nutrition. 136 (1), 202-206 (2006).</li>
<li>Choukem, S. -P., Gautier, J. -F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((How+to+measure+hepatic+insulin+resistance%5BTitle%5D)+AND+%22Diabetes+Metabolism%22%5BJournal%5D)">How to measure hepatic insulin resistance.</a> Diabetes Metabolism. 34 (6), Pt 2 664-673 (2008).</li>
</ol>

The authors have nothing to disclose.

Hyperglycemia and abnormal glucose metabolism/homeostasis are features of PCOS. Blood glucose level is maintained by a combination of glucose from diet and glucose production via glycogenolysis and gluconeogenesis and glycogenesis, under the control of hormone and enzymes. Hepatic glucose production is suppressed by the presence of increased circulating glucose levels. In disorders of abnormal glucose metabolism, regulation of the suppression of glucose production is compromised leading to hyperglycemia. While m...

Polycystic ovary syndrome (PCOS) is a common disorder occurring in 12%-20% of reproductive-aged women1,2. It is a complex disease resulting in variable phenotypes involving polycystic ovaries, irregular menses and clinical or laboratory evidence of hyperandrogenemia, and is typically diagnosed when a woman meets two of the three criteria3. A predominant aspect of PCOS, and a key factor in its pathogenesis, is metabolic derangements that are found in women who have the disease. Women with PCOS have higher incidences of insulin resistance, glucose intolerance, obesity, and metabolic syndrome3,4,5,6. Insulin resistance is not only a manifestation of the disease, but it is thought to contribute to its pathogenesis by potentiating the action of luteinizing hormone in the ovary thereby leading to increased androgen production7,8. Insulin resistance is thought to have several possible origins but studies suggest it may be due to abnormal patterns of insulin receptor signaling9,10. Studies have evaluated insulin resistance in PCOS patients using the gold standard technique of hyperinsulinemic-euglycemic clamp11,12,13,14,15. Women with PCOS, irrespective of BMI, have higher levels of insulin resistance compared with controls. Insulin control over glucose production is impaired in disorders of insulin resistance leading to excess glucose production. For example, diabetic patients have increased rates of gluconeogenesis and impaired suppression of glycogenolysis16. Furthermore, impaired suppression of glucose production has been observed in diabetic rats17. Although clamp studies can give a measurement of insulin resistance, few studies in PCOS focus on direct measurement of glucose production in fasting and fed states. This requires the use of a non-radioactive isotopic glucose tracer infusion and measurement via mass spectrometry.
Animal models have been extensively used in PCOS research. Both lean and obese-type PCOS murine models have been created by administering androgens prenatally, prepubertally, or post-pubertally18. Rodent PCOS models also demonstrate metabolic differences compared with their respective controls. Previous data from our lab demonstrated abnormal glucose tolerance tests (GTT) in PCOS mouse models (lean and obese), consistent with human PCOS literature19. Use of a lean and obese animal model allows further investigation into metabolic differences. Specifically, this model allows evaluation of the rate of glucose production directly using isotopic glucose tracers. One of the most commonly used stable isotopic glucose tracer is [6,6-2H2]glucose. The [6,6-2H2]glucose enrichment can be measured using a pentaacetate derivative as previously described20.
In this study, our aim was to measure the rate of hepatic glucose production in fasting and glucose-rich state in PCOS mice using isotopic glucose infusion. These techniques can be applied to a wide range of experiments involving glucose kinetics.

<table><tbody><tr><td>0.9% sodium chloride solution</td><td>McKesson</td><td>275595</td><td></td></tr><tr><td>10 mL BD Luer-Lok tip syringe</td><td>VWR</td><td>75846-756</td><td>Two syringes per animal (one for isotopic glucose solution, one for glucose-rich isotopic solution)</td></tr><tr><td>1-inch clear transpore tape</td><td>3M</td><td>70200400169</td><td></td></tr><tr><td>1-inch Labeling tape</td><td>Fisher</td><td>GS07F161BA</td><td>Brand is example</td></tr><tr><td>5 mL syringe containing heparanized saline flush</td><td>McKesson</td><td>191-MIH-2235</td><td>One can also prepare a heparin flush solution (10 units/mL heparin in 0.9% sodium chloride)</td></tr><tr><td>5 mm Medipoint Goldenrod animal lancets</td><td>Fisher Scientific</td><td>NC9891620</td><td>5 mm if animal is between 2 and 6 months</td></tr><tr><td>Acetone</td><td>Sigma-Aldrich</td><td>650501</td><td></td></tr><tr><td>Advanced hot plate stirrer</td><td>VWR</td><td>97042-602</td><td>Brand is example</td></tr><tr><td>BD 27 gauge 0.5 inch needles</td><td>Health Warehouse</td><td>A283952</td><td></td></tr><tr><td>BD 30 gauge 0.5 inch needles</td><td>Medvet</td><td>305106</td><td></td></tr><tr><td>BD Intramedic Polyethylene (PE) tubing 0.28 mm ID x 0.61 mm</td><td>VWR</td><td>63019-004</td><td></td></tr><tr><td>BD Intramedic Polyethylene (PE) tubing 0.28 mm ID x 0.61 mm</td><td>VWR</td><td>63019-004</td><td></td></tr><tr><td>Beaker, 1000 mL</td><td></td><td></td><td>Any brand</td></tr><tr><td>Caging pellets</td><td></td><td></td><td></td></tr><tr><td>Clear VOA glass vials with closed-top cap</td><td>Fisher Scientific</td><td>05-719-120</td><td>For storage of acetone and blood draw samples</td></tr><tr><td>Copper toothless alligator clamp for tourniquet</td><td>Amazon</td><td></td><td>Any Brand; smooth toothless alligator clips made of solid copper</td></tr><tr><td>D-(+)-glucose &gt;99.5%</td><td>Sigma-Aldrich</td><td>G8270</td><td></td></tr><tr><td>D-glucose (6,6-D2, 99%)</td><td>Cambridge Isotope Laboratories, Inc.</td><td>DLM-349-PK</td><td></td></tr><tr><td>Dow Corning silastic tubing 0.3 mm ID x 0.64 mm OD</td><td>VWR</td><td>62999-042</td><td></td></tr><tr><td>Magnifying glass</td><td>Amazon</td><td></td><td>Any brand; similar to LANCOSC Magnifying Glass with Light and Stand</td></tr><tr><td>Microbalance</td><td>Ohaus Adventurer Pro</td><td>AV264C</td><td>Any similar model with 0.0001g accuracy can be used</td></tr><tr><td>Nalgene bottle, 500 mL</td><td>Sigma-Aldrich</td><td>B0158-12EA</td><td>Or any Similar brand; saw in half (including lid) and cut tail-sized notch in the bottom</td></tr><tr><td>PHD Ultra multi-syringe pump</td><td>Harvard Apparatus</td><td>70-3024A</td><td></td></tr><tr><td>Plexiglass sheet</td><td></td><td></td><td>Any brand; to stabalize mouse during catheter insertion</td></tr><tr><td>Plexiglass sheets and dividers</td><td></td><td></td><td>Any brand; used to cage mice during infusion</td></tr></tbody></table>

evaluation of hepatic glucose production in a polycystic ovary syndrome mouse model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Polycystic ovary syndrome (PCOS) is a common disease that results in disorders of glucose metabolism, such as insulin resistance and glucose intolerance. Dysregulated glucose metabolism is an important manifestation of the disease and is the key to its pathogenesis. Therefore, studies involving evaluation of glucose metabolism in PCOS are of utmost importance. Very few studies have quantified hepatic glucose production directly in PCOS models using non-radioactive glucose tracers. In this study, we discuss step-by-step instructions for the quantification of the rate of hepatic glucose production in a PCOS mouse model by measuring M+2 enrichment of [6,6-2H2]glucose, a stable isotopic glucose tracer, via gas chromatography - mass spectrometry (GCMS). This procedure involves creation of stable isotopic glucose tracer solution, use of tail vein catheter placement and infusion of the glucose tracer in both fasting and glucose-rich states in the same mouse in tandem. The enrichment of [6,6-2H2]glucose is measured using pentaacetate derivative in GCMS. This technique can be applied to a wide variety of studies involving direct measurement of the rate of hepatic glucose production.

Using previously described isotope dilution equations, the total plasma glucose rate (glucoseRa) was calculated from M+2 enrichment of [6,6-2H2]glucose in fasting and glucose-rich conditions using the pentaacetate derivative21. Under steady-state conditions, it is assumed that rate of appearance of glucose is equal to the rate of disappearance of glucose. In the control group, the total glucoseRa was 19.98 ± 2.53 mg/(kg·min) after 6 h fasting and 25.80 ±...

This study describes the direct measurement of hepatic glucose production in a polycystic ovary syndrome mouse model by using a stable isotopic glucose tracer via tail vein in both fasting and glucose-rich states in tandem.

Polycystic ovary syndrome (PCOS) is a common disease that results in disorders of glucose metabolism, such as insulin resistance and glucose intolerance. ...

evaluation-hepatic-glucose-production-polycystic-ovary-syndrome-mouse

Research

JoVE Journal

Medicine

The hyperinsulinemic-euglycemic clamp, or insulin clamp, is the gold standard for assessing insulin action in vivo.  A method for performing insulin clamps in mice is described.  This includes a method for arterial catheterization that permits experiments to be performed in conscious, unrestrained mice with minimal stress.

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

This video introduces how to perform an oral glucose tolerance test on a laboratory mouse.

Oral Glucose Tolerance Test (OGTT): Measuring Glucose Metabolism in Mice

This article describes a way to prepare and insert dihydrotestosterone (DHT) pellets to model Polycystic Ovary Syndrome (PCOS) in mice. The example protocol demonstrates the procedure in mice used for reproductive and metabolic studies.

Subcutaneous Dihydrotestosterone (DHT) Treatment: Mouse Model of Polycystic Ovary Syndrome (PCOS)

Here, optimized methods to generate in vivo and in vitro models of hepatic steatosis and to analyze the steatotic phenotypes and related physiological parameters are described.

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

The current article describes the generation and metabolic characterization of high-fat diet-fed mice as a model of diet-induced insulin resistance and obesity. It further features detailed protocols to perform the oral glucose tolerance test and the insulin tolerance test, monitoring whole-body alterations of glucose metabolism in vivo.

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

We describe the development of a lean PCOS-like mouse model with dihydrotestosterone pellet to study the pathophysiology of PCOS and the offspring from these PCOS-like dams.

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Primary hepatocytes are a valuable tool to study liver response and metabolism in vitro. Utilizing commercially available reagents, an improved time- and labor-efficient protocol for mouse primary hepatocyte isolation was developed.

An Improved Time- and Labor- Efficient Protocol for Mouse Primary Hepatocyte Isolation

Fatty acid β-oxidation is an essential metabolic pathway responsible for generating energy in many different cell types, including hepatocytes. Here, we describe a method to measure fatty acid β-oxidation in freshly isolated primary hepatocytes using 14C-labeled palmitic acid.

Measurement of Fatty Acid &#946;-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Here, we present a robust method for in situ perfusion of the mouse liver to study the acute and direct regulation of liver metabolism without disturbing the hepatic architecture but in the absence of extra-hepatic factors.

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

This protocol introduces a technique for inducing polycystic ovary syndrome (PCOS) models in mice through controlled letrozole release using mini-pumps. Under adequate anesthesia, the mini-pump was implanted subcutaneously, and PCOS was successfully induced in the mice after a certain period of the mini-pump release.

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Learn to quantify hepatic glucose production in a PCOS mouse model using stable isotopic glucose tracers and GCMS analysis. This method enables accurate measurement of metabolic dysregulation in fasting and glucose-rich states.

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Explore More Videos